Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Impaired Hepatic Function Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

NCT00418626

View directory record Official record

Conditions: Healthy
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Male only

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Source: ClinicalTrials.gov public record

Updated Mar 7, 2012 · Synced May 22, 2026, 12:51 AM EDT

Not listed No phase listed Observational

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

NCT03767803

View directory record Official record

Conditions: Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Headache, Visual Impairment
Interventions: Non-interventional study; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only

Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: San Diego, California • Newark, Delaware • Boca Raton, Florida + 19 more

Source: ClinicalTrials.gov public record

Updated Jan 22, 2020 · Synced May 22, 2026, 12:51 AM EDT

Withdrawn Phase 1 Interventional

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

NCT04398680

View directory record Official record

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2025 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347

View directory record Official record

Conditions: Liver Diseases
Interventions: Osivelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 9, 2025 · Synced May 22, 2026, 12:51 AM EDT

Active, not recruiting Phase 1 Interventional

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT02626312

View directory record Official record

Conditions: Cholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions: Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Other · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 29, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634

View directory record Official record

Conditions: Hepatic Impairment
Interventions: envudeucitinib; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Lake Forest, California • Miami Lakes, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

NCT01392807

View directory record Official record

Conditions: Hepatic; Functional Disturbance
Interventions: NKTR-118; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Source: ClinicalTrials.gov public record

Updated Oct 14, 2014 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

NCT02509624

View directory record Official record

Conditions: Diabetic Kidney Disease
Interventions: Selonsertib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older

Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 5
States / cities: Denver, Colorado • Miami, Florida • Orlando, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 26, 2021 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942

View directory record Official record

Conditions: Hepatic Impairment
Interventions: KD025; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 17, 2022 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795

View directory record Official record

Conditions: Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions: MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 4, 2023 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322

View directory record Official record

Conditions: Liver Diseases, Healthy
Interventions: Zongertinib (BI 1810631); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Aug 14, 2025 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

NCT02521376

View directory record Official record

Conditions: Oncology
Interventions: Entospletinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 25, 2019 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

NCT00437424

View directory record Official record

Conditions: Carcinoma, Hepatocellular
Interventions: Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Clleveland, Ohio + 1 more

Source: ClinicalTrials.gov public record

Updated May 3, 2011 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

NCT01186588

View directory record Official record

Conditions: Healthy, Hepatic Insufficiency
Interventions: Canagliflozin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated May 28, 2013 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

NCT00741273

View directory record Official record

Conditions: Impaired Liver Function
Interventions: Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 62 Years · Female only

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Aug 27, 2014 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770

View directory record Official record

Conditions: Solid Tumours
Interventions: AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more

Source: ClinicalTrials.gov public record

Updated Mar 7, 2019 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180

View directory record Official record

Conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions: TVB-2640 - 50 mg; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Dec 25, 2023 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481

View directory record Official record

Conditions: Solid Tumors, Hepatic Impairment
Interventions: Dovitinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Durham, North Carolina • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Dec 20, 2020 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Hepatic Impairment Study for PF-04965842.

NCT03626415

View directory record Official record

Conditions: Hepatic Impairment
Interventions: PF-04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated May 17, 2020 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 4 Interventional Results available

Acute Effect of Exenatide on Brain Glucose Metabolism

NCT01588418

View directory record Official record

Conditions: Impaired Glucose Tolerance (IGT), Diabetes
Interventions: Exenatide, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years · Male only

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Nov 23, 2017 · Synced May 22, 2026, 12:51 AM EDT

Recruiting Phase 1 Interventional

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT07342868

View directory record Official record

Conditions: Chronic Hepaititis B Infections
Interventions: Pevifoscorvir Sodium (ALG-000184); Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Feb 3, 2026 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

NCT03962049

View directory record Official record

Conditions: Hepatic Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 75 Years · Female only

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jan 12, 2020 · Synced May 22, 2026, 12:51 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

NCT05098054

View directory record Official record

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Feb 1, 2024 · Synced May 22, 2026, 12:51 AM EDT

Completed Not applicable Interventional Results available

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

NCT01439854

View directory record Official record

Conditions: Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jul 2, 2025 · Synced May 22, 2026, 12:51 AM EDT